Disease · MONDO_0005136

malaria

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. malaria. Diseases, record MONDO_0005136. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005136

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: malaria; Open Targets
Open Targets ID: MONDO_0005136; Open Targets
Other names: Disease due to Plasmodiidae, Disease due to Plasmodiidae (disorder), Fever, Marsh, Fever, Remittent, INFECT PLASMODIUM, Induced malaria (disorder), Infection, Plasmodium, Infections, Plasmodium, MALARIA COMPLICATED NEC, MALARIA NEC, MALARIA NOS, Malaria (disorder), Malaria, unspecified, Malarial fever, Malarial fever (finding), Marsh Fever, Other malaria, Other malaria (disorder), Other pernicious complications of malaria, PLASMODIUM INFECT, Paludism, Plasmodiosis, Plasmodium Infection, Plasmodium Infections, Remittent Fever, Unspecified malaria, Unspecified malaria (disorder), [X]Unspecified malaria, [X]Unspecified malaria (disorder), induced malaria, malaria infection; Open Targets
Disease Ontology: DOID:12365; Disease Ontology
MeSH: D008288; MeSH
NCI Thesaurus: C34797; NCI Thesaurus
Orphanet: ORPHA:673; Orphanet
Highest stage of its drugs: Approval, for 37 of its 102 drugs, from ATC, DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs102

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ARTEMETHER	CHEMBL566534	Small molecule	Approval	ATC, DailyMed, PMDA and TTD	97	93	89	Drugs and targets
LUMEFANTRINE	CHEMBL38827	Small molecule	Approval	DailyMed, PMDA and TTD	90	87	84	Drugs and targets
ARTESUNATE	CHEMBL361497	Small molecule	Approval	ATC, DailyMed, EMA Human Drugs, FDA and TTD	91	85	84	Drugs and targets
AMODIAQUINE	CHEMBL682	Small molecule	Approval	ATC and TTD	51	48	47	Drugs and targets
PIPERAQUINE	CHEMBL303933	Small molecule	Approval	TTD	42	41	40	Drugs and targets
ARTENIMOL	CHEMBL307261	Small molecule	Approval	ATC, EMA Human Drugs and TTD	42	38	37	Drugs and targets
LUMEFANTRINE CO-ARTEMETHER	CHEMBL4297927		Approval	PMDA	38	37	2	Drugs and targets
PRIMAQUINE	CHEMBL506	Small molecule	Approval	ATC and TTD	25	23	23	Drugs and targets
CHLOROQUINE	CHEMBL76	Small molecule	Approval	ATC and TTD	24	21	21	Drugs and targets
PYRIMETHAMINE	CHEMBL36	Small molecule	Approval	ATC, DailyMed and TTD	24	20	19	Drugs and targets

1 to 10 of 102

See all 102 drugs

Targets54

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CYP3A4	Cytochrome P450 3A	2	Cytochrome P450 3A inhibitor	Phase 3	https://conductscience.org/library/genes/1576	Drugs and targets
CYP3A43	Cytochrome P450 3A	2	Cytochrome P450 3A inhibitor	Phase 3	https://conductscience.org/library/genes/64816	Drugs and targets
CYP3A5	Cytochrome P450 3A	2	Cytochrome P450 3A inhibitor	Phase 3	https://conductscience.org/library/genes/1577	Drugs and targets
CYP3A7	Cytochrome P450 3A	2	Cytochrome P450 3A inhibitor	Phase 3	https://conductscience.org/library/genes/1551	Drugs and targets
TLR7	Toll-like receptor 7	2	Toll-like receptor 7 antagonist	Approval	https://conductscience.org/library/genes/51284	Drugs and targets
TLR9	Toll-like receptor 9	2	Toll-like receptor 9 antagonist	Approval	https://conductscience.org/library/genes/54106	Drugs and targets
ABL1	Bcr/Abl fusion protein	1	Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor	Phase 2	https://conductscience.org/library/genes/25	Drugs and targets
BCR	Bcr/Abl fusion protein	1	Bcr/Abl fusion protein inhibitor	Phase 2	https://conductscience.org/library/genes/613	Drugs and targets
DHFR	Dihydrofolate reductase	1	Dihydrofolate reductase inhibitor	Phase 1	https://conductscience.org/library/genes/1719	Drugs and targets
EPOR	Erythropoietin receptor	1	Erythropoietin receptor agonist	Phase 2/3	https://conductscience.org/library/genes/2057	Drugs and targets

1 to 10 of 54

See all 54 targets

Trials222

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 8 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00513500	Zambia Integrated Management of Malaria and Pneumonia Study	Not applicable	3,125	2010-07-13	Pneumonia, Malaria	AMOXICILLIN, ARTEMETHER, LUMEFANTRINE	Its record names the disease	ClinicalTrials.gov
NCT02509481	Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study	Phase 2/3	2,712	2019-01-04	Malaria, Lymphatic Filariasis	ALBENDAZOLE, IVERMECTIN	Its record names the disease	ClinicalTrials.gov
NCT00297882	Artemisinin-Based Combination Therapy: Clinical Trials in Cameroon	Phase 3	816	2021-06-08	Malaria	AMODIAQUINE, ARTEMETHER, ARTESUNATE, LUMEFANTRINE	Its record names the disease	ClinicalTrials.gov
NCT00089505	NNRTI vs PI Regimens for HIV Infected Women After They Have Taken Nevirapine to Prevent Mother-To-Child HIV Transmission	Phase 3	745	2011-02-04	HIV Infections	EMTRICITABINE, LOPINAVIR, NEVIRAPINE, RITONAVIR, TENOFOVIR DISOPROXIL FUMARATE	Its record names the disease	ClinicalTrials.gov
NCT00379821	Chloroquine Alone or in Combination for Malaria in Children in Malawi	Phase 3	640	2011-07-27	Plasmodium Falciparum Infection	ARTESUNATE, ATOVAQUONE, AZITHROMYCIN, CHLOROQUINE, PROGUANIL	Its record names the disease	ClinicalTrials.gov
NCT00541385	Pyronaridine Artesunate 3:1 Granule Formulation vs. Coartem© Crushed Tablets in P. Falciparum Malaria Pediatric Patients	Phase 3	535	2021-11-22	Malaria	ARTESUNATE, PYRONARIDINE	Its record names the disease	ClinicalTrials.gov
NCT01594931	Phase II Dose-ranging Study of Pyronaridine/Artesunate in Adults Patients With Plasmodium Falciparum Malaria	Phase 2	477	2021-09-17	Plasmodium Falciparum Malaria	ARTESUNATE, PYRONARIDINE	Its record names the disease	ClinicalTrials.gov
NCT02497612	To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine and Artefenomel in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria	Phase 2	377	2020-10-19	Plasmodium Falciparum Infection	ARTEFENOMEL	Its record names the disease	ClinicalTrials.gov
NCT00677833	Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated P. Falciparum Malaria In Children In Africa	Phase 2/3	361	2014-06-26	Malaria, Falciparum	AZITHROMYCIN, CHLOROQUINE	Its record names the disease	ClinicalTrials.gov
NCT03453840	Extended Duration Artemether-lumefantrine Treatment for Malaria in Children	Phase 4	305	2025-01-03	Uncomplicated Plasmodium Falciparum Malaria	ARTEMETHER, LUMEFANTRINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 222

See all 222 trials

Comparisons in its trials43

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Enhanced Treatment vs Current Practice: serious adverse events	6 of 1,017	15 of 2,108	3,125	NCT00513500	Trial comparisons
Enhanced Treatment vs Current Practice: Number of Children With Fever Who Received Coartem (Artemether-lumefantrine)	265 of 963	2,066 of 2,084	3,047	NCT00513500	Trial comparisons
Single MDA vs Repeated MDA: deaths from any cause	5 of 1,265	15 of 1,447	2,712	NCT02509481	Trial comparisons
Single MDA vs Repeated MDA: serious adverse events	10 of 1,265	19 of 1,447	2,712	NCT02509481	Trial comparisons
1 Artemether-Lumefantrine vs 2 Amodiaquine-Artesunate: Cure Rate Day 14	192 of 204	563 of 612	816	NCT00297882	Trial comparisons
1 Artemether-Lumefantine (AL) vs 2 Amodiaquine-Artesunate (AQ-AS): deaths from any cause	2 of 204	2 of 612	816	NCT00297882	Trial comparisons
1 Artemether-Lumefantrine AL vs 2 Amodiaquine-Artesunate AQ-AS: Cure Rate on Day 28	197 of 204	603 of 612	816	NCT00297882	Trial comparisons
1 Artemether-Lumefantine (AL) vs 2 Amodiaquine-Artesunate (AQ-AS): serious adverse events	6 of 204	3 of 612	816	NCT00297882	Trial comparisons
Enhanced Treatment vs Current Practice: Number of Children Who do Not Respond to Treatment for Pneumonia	41 of 362	41 of 203	565	NCT00513500	Trial comparisons
PA Group vs AL Group: deaths from any cause	0 of 355	0 of 180	535	NCT00541385	Trial comparisons

1 to 10 of 43

See all 43 comparisons in its trials

Papers from its trials210

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42326839	RESULT	1	PubMed
40670924	RESULT	2	PubMed
39853752	RESULT	1	PubMed
38013152	RESULT	1	PubMed
37611122	RESULT	1	PubMed
36289202	RESULT	1	PubMed
36130191	RESULT	1	PubMed
34715032	RESULT	1	PubMed
30698522	RESULT	1	PubMed
29482720	RESULT	1	PubMed

1 to 10 of 210

See all 210 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005136

GET https://conductscience.org/api/diseases/v1/MONDO_0005136/drugs?page=2

API reference For AI assistants